{"title":"秋水仙碱仅抑制高剂量NLRP3炎症小体- COVID-19和流感并发症的主要原因","authors":"Vanyo Mitev, Georgi Momekov","doi":"10.31083/FBL44744","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the enormous theoretical progress, there is currently no effective treatment for the cytokine storm (CS) in COVID-19 and Influenza, which is due to hyperactivation of NOD-like receptor protein 3 inflammasome (NLRP3-I). According to our research, the only way to prevent or interrupt the CS is to administer high but safe doses of colchicine, which inhibits NLRP3-I/CS.</p>","PeriodicalId":73069,"journal":{"name":"Frontiers in bioscience (Landmark edition)","volume":"30 9","pages":"44744"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Colchicine Only Inhibits in Higher Doses Hyperactivated NLRP3 Inflammasome-The Main Respondent for Complications in COVID-19 and Influenza.\",\"authors\":\"Vanyo Mitev, Georgi Momekov\",\"doi\":\"10.31083/FBL44744\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Despite the enormous theoretical progress, there is currently no effective treatment for the cytokine storm (CS) in COVID-19 and Influenza, which is due to hyperactivation of NOD-like receptor protein 3 inflammasome (NLRP3-I). According to our research, the only way to prevent or interrupt the CS is to administer high but safe doses of colchicine, which inhibits NLRP3-I/CS.</p>\",\"PeriodicalId\":73069,\"journal\":{\"name\":\"Frontiers in bioscience (Landmark edition)\",\"volume\":\"30 9\",\"pages\":\"44744\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in bioscience (Landmark edition)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31083/FBL44744\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in bioscience (Landmark edition)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31083/FBL44744","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Colchicine Only Inhibits in Higher Doses Hyperactivated NLRP3 Inflammasome-The Main Respondent for Complications in COVID-19 and Influenza.
Despite the enormous theoretical progress, there is currently no effective treatment for the cytokine storm (CS) in COVID-19 and Influenza, which is due to hyperactivation of NOD-like receptor protein 3 inflammasome (NLRP3-I). According to our research, the only way to prevent or interrupt the CS is to administer high but safe doses of colchicine, which inhibits NLRP3-I/CS.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
